ArticleACS nano2014
Self-titrating anticoagulant nanocomplexes that restore homeostatic regulation of the coagulation cascade.
Article in ACS nano, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Progress of nanomaterials in the treatment of thrombus.Drug delivery and translational research · 2024Review
- A thrombin-triggered self-regulating anticoagulant strategy combined with anti-inflammatory capacity for blood-contacting implants.Science advances · 2022Article
- Combination strategies for antithrombotic biomaterials: an emerging trend towards hemocompatibility.Biomaterials science · 2021Article
- Nanomedicine for Acute Brain Injuries: Insight from Decades of Cancer Nanomedicine.Molecular pharmaceutics · 2021Review
- Heparin reversal by an oligoethylene glycol functionalized guanidinocalixarene.Chemical science · 2020Article
- Vascular Nanomedicine: Current Status, Opportunities, and Challenges.Seminars in thrombosis and hemostasis · 2020Review
- Accelerating thrombolysis using a precision and clot-penetrating drug delivery strategy by nanoparticle-shelled microbubbles.Science advances · 2020Article
- Cross-linker-Modulated Nanogel Flexibility Correlates with Tunable Targeting to a Sterically Impeded Endothelial Marker.ACS nano · 2019Article
- Protease activity sensors noninvasively classify bacterial infections and antibiotic responses.EBioMedicine · 2018Article
- Advances in bioresponsive closed-loop drug delivery systems.International journal of pharmaceutics · 2018Review
- Designing hydrogels for controlled drug delivery.Nature reviews. Materials · 2016Article
- Comparison of Modular PEG Incorporation Strategies for Stabilization of Peptide-siRNA Nanocomplexes.Bioconjugate chemistry · 2016Article
- Smart nanosystems: Bio-inspired technologies that interact with the host environment.Proceedings of the National Academy of Sciences of the United States of America · 2015Review
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
Abstract
Antithrombotic therapy is a critical portion of the treatment regime for a number of life-threatening conditions, including cardiovascular disease, stroke, and cancer; yet, proper clinical management of anticoagulation remains a challenge because existing agents increase the propensity for bleeding in patients. Here, we describe the development of a bioresponsive peptide-polysaccharide nanocomplex that utilizes a negative feedback mechanism to self-titrate the release of anticoagulant in response to varying levels of coagulation activity. This nanoscale self-titrating activatable therapeutic, or nanoSTAT, consists of a cationic thrombin-cleavable peptide and heparin, an anionic polysaccharide and widely used clinical anticoagulant. Under nonthrombotic conditions, nanoSTATs circulate inactively, neither releasing anticoagulant nor significantly prolonging bleeding time. However, in response to life-threatening pulmonary embolism, nanoSTATs locally release their drug payload and prevent thrombosis. This autonomous negative feedback regulator may improve antithrombotic therapy by increasing the therapeutic window and decreasing the bleeding risk of anticoagulants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.